Whitaker Myers Wealth Managers LTD. Raises Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Whitaker Myers Wealth Managers LTD. lifted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 965 shares of the medical equipment provider’s stock after acquiring an additional 51 shares during the period. Whitaker Myers Wealth Managers LTD.’s holdings in Intuitive Surgical were worth $474,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Chicago Capital LLC increased its position in Intuitive Surgical by 8.0% in the 3rd quarter. Chicago Capital LLC now owns 31,575 shares of the medical equipment provider’s stock valued at $15,512,000 after acquiring an additional 2,331 shares during the period. Commonwealth Equity Services LLC grew its stake in shares of Intuitive Surgical by 3.6% in the 3rd quarter. Commonwealth Equity Services LLC now owns 69,995 shares of the medical equipment provider’s stock valued at $34,386,000 after purchasing an additional 2,456 shares during the last quarter. Raymond James & Associates increased its holdings in shares of Intuitive Surgical by 25.4% in the third quarter. Raymond James & Associates now owns 380,886 shares of the medical equipment provider’s stock valued at $187,118,000 after purchasing an additional 77,119 shares during the period. Slow Capital Inc. raised its stake in shares of Intuitive Surgical by 0.7% during the third quarter. Slow Capital Inc. now owns 40,632 shares of the medical equipment provider’s stock worth $19,961,000 after purchasing an additional 267 shares during the last quarter. Finally, Friedenthal Financial purchased a new position in Intuitive Surgical in the 3rd quarter valued at $51,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the sale, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at $1,461,006.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Mark Brosius sold 2,115 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the sale, the insider now owns 295 shares in the company, valued at approximately $145,113.45. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock valued at $25,528,753 over the last quarter. Insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

ISRG has been the subject of several recent analyst reports. BTIG Research set a $535.00 target price on shares of Intuitive Surgical in a research note on Friday. Citigroup raised their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Wells Fargo & Company increased their target price on Intuitive Surgical from $466.00 to $549.00 and gave the stock an “overweight” rating in a research note on Friday. Piper Sandler restated an “overweight” rating and issued a $538.00 price target (up from $495.00) on shares of Intuitive Surgical in a research note on Friday. Finally, Morgan Stanley upped their price objective on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $513.74.

Intuitive Surgical Price Performance

ISRG stock opened at $521.15 on Friday. The company’s 50 day simple moving average is $483.85 and its 200-day simple moving average is $438.17. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $523.34. The firm has a market capitalization of $184.85 billion, a PE ratio of 94.07, a P/E/G ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter in the prior year, the firm earned $1.18 EPS. Intuitive Surgical’s quarterly revenue was up 14.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.